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Abstract
Peripheral T cell lymphomas (PTCLs) are associated with a poor prognosis due to often advanced disease at the time of
diagnosis and due to a lack of efficient therapeutic options. Therefore, appropriate animal models of PTCL are vital to
improve clinical management of this disease. Here, we describe a monoclonal CD8
+ CD4
2 ab T cell receptor Vb2
+ CD28
+ T
cell lymphoma line, termed T8-28. T8-28 cells were isolated from an un-manipulated adult BALB/c mouse housed under
standard pathogen-free conditions. T8-28 cells induced terminal malignancy upon adoptive transfer into syngeneic BALB/c
mice. Despite intracellular expression of the cytotoxic T cell differentiation marker granzyme B, T8-28 cells appeared to be
defective with respect to cytotoxic activity as read-out in vitro. Among the protocols tested, only addition of interleukin 2 in
vitro could partially compensate for the in vivo micro-milieu in promoting growth of the T8-28 lymphoma cells.
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Introduction
To develop novel therapeutic strategies for peripheral T cell
lymphoma (PTCL) appropriate animal models are crucial [1].
While researchers have been isolating, and also wrongly re-
isolating [2], transplantable T cell lymphoma lines since the 1940s
from mice after chemical tumor induction/promotion [3], only
recently the ectopic expression of an inducible T cell kinase (ITK)-
spleen tyrosine kinase (SYK) fusion gene has allowed to establish
the first mouse model of PTCL [1,4,5]. To what extent even these
genetically induced neoplasias resemble their human pendants is,
of course, unclear. Therefore, isolation and characterization of the
T8-28 cell line from an un-manipulated BALB/c mouse will be
instrumental in furthering our understanding of lymphomagenesis
in mice and will help to develop successful therapies for PTCL in
humans.
Results and Discussion
T8-28 cells were initially isolated from an un-manipulated adult
male BALB/c.OlaHsd mouse kept under standard housing
conditions. The animal was found to be paraparetic and, thus,
killed for humane reasons. Upon necropsy, spleen and lymph
nodes were grossly enlarged containing 1.0610
9 and 1.7610
9
cells, respectively. To determine, whether the secondary lymphoid
organ cell suspensions of this animal contained transplantable
tumor cells, we injected 1610
7 or 5610
6 splenocytes intravenously
into syngeneic BALB/c mice, which induced terminal malignancy
in the recipient mice after 12 and 16 days, respectively, (Figure 1A)
with splenocyte numbers ranging from 4.5610
8 to 1.7610
9 cells in
post-mortem analyses. Tumorigenicity of the splenocytes we had
isolated was further tested under clinically relevant conditions [6]
by injecting 3610
3 cells into lethally irradiated BALB/c.OlaHsd
mice followed by re-constitution of hematopoiesis using T cell-
depletetd bone marrow cells isolated from C57BL/6 mice. In this
scenario terminal malignancy developed with a median of 33 days
(Figure 1A).
The splenocytes we had transplanted consisted by more than
95% of CD8ab
+ CD4
2 CD3
+ TCR
+ and CD28
+ T cells as
revealed by fluorescence-activated cell sorting analysis (Figure 1B,
D), indicating that we had isolated a T cell lymphoma which we
termed T8-28. Moreover, comparing the lymphoma cells with
freshly isolated normal mouse T cells by light microscopy showed
that they, indeed, had a lymphoblastic morphology (Figure 1C)
further corroborating our diagnosis.
The overall expression of lineage and activation markers,
including CD25, Ki-67 and granzyme B (Figure 1D and Table
S1), suggested that the T8-28 cells largely resembled fully
differentiated cytotoxic T cells with an, at most, oligoclonal
TCR repertoire comprising only Vb2
+ cells (Figure 1E). Polymer-
ase chain reaction DNA sequencing confirmed an in-frame
rearrangement of TCR Vb2 and produced a single complemen-
tarity-determining region (CDR) 3 sequence revealing that the T8-
28 cells actually constitute a monoclonal population. Moreover,
knowledge of the CDR3 sequence used by T8-28 cells will allow to
track micro-metastases in future experiments in vivo. Therefore, the
T8-28 lymphoma is a peripheral T cell lymphoma most likely
stemming from a transformed mature CD8
+ T cell.
Although T8-28 cells expressed markers of cytotoxic T cells
they, however, failed to mediate cytotoxicity in re-directed lysis
assays against A20J target cells which were readily killed by
syngeneic Con A blasts after TCR cross-linking (Figure 2A). Apart
from defective effector functions, de-differentiation of malignant
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we analyzed the growth characteristics of T8-28 cells in vitro.
Culture of T8-28 cells in medium only led to a rapid decline in cell
numbers which was stalled for one day by the addition of
recombinant mouse interleukin 15 or 7 and partially reverted by
the addition of recombinant human interleukin 2 (Figure 2B). So
far, long-term in vitro culture of the T8-28 cells beyond day five
has, however, not been possible.
Combining recombinant human interleukin 2 with stimulation
of CD3 and/or CD28 via bead-coupled monoclonal antibodies led
to poorer cell recovery as compared to cultures in the presence of
recombinant human interleukin 2 alone (Figure 2C). Bypassing
Figure 1. In vivo tumorigenicity of and T cell marker expression by T8-28 cells. (A) Survival of unmanipulated BALB/c.OlaHsd mice
transplanted with 1610
7 (experiment 1; n=2) or 5610
6 (experiment 2; n=2) T8-28 cells or irradiated BALB/c.OlaHsd mice transplanted with 3610
3
T8-28 cells on day 0 (pooled data of two experiments; n=10). (B) CD4, CD8a and CD3 expression by T8-28 cells. Figures indicate the percentages of
cells in the respective quadrants. (C) Cytospins of T8-28 and freshly isolated mouse T cells stained by the Diff-QuikH method. Original magnification
was 630-fold. Microscope: LEICA DMIRE2. Camera: LEICA DFC300 FX. Acquisition Software: LEICA IM50 Image Manager. Adobe Photoshop CS3 was
used to obtain the close-ups shown. (D) Fluorescence-activated cell sorting analysis of T cell lineage and activation markers as indicated (black
histograms). Staining controls (grey histograms): i, v, isotype-matched control mAb; ii,vi, non-isotype-matched control mAb; iii, no primary mAb; iv:
identical control staining as in iii. (E) Expression of TCRVb chains by T8-28 cells and CD4
2 CD8
+ T cells of a normal BALB/c mouse as indicated. Grey
histograms represent overlays of the 14 remaining TCRVb chains (Vb3–Vb18) detected by the kit used. (F) The genetic setup and primary structure of
the TCR CDR3 region was analyzed by polymerase chain reaction DNA sequencing and the IMGT/V-QUEST program. Please note that TRBV1 in the
IMGT nomenclature is identical to designation as Vb2 used throughout this paper and that the *01 allele has originally been found in BALB/c mice
which is consistent with the origin of the T8-28 cells. The sequenced Cb part (not shown) could be identified as Cb2 as expected for a TCR-chain using
the second DJ cluster.
doi:10.1371/journal.pone.0028546.g001
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reduced the frequency of viable cells, in this case from 76% to 27%
(Figure 2D). These data suggest that the downstream signaling
machinery of the TCR complex and CD28 is principally intact in
T8-28 cells and that the observed induction of cell death upon
stimulation of these pathways may be harnessed for therapeutic
purposes. Pre-cautions [7,8], however, need to be taken when
targeting either the TCR complex or CD28 with monoclonal
antibodies in humans as a profound activation of normal T cells
may induce a toxic ‘cytokine storm’ [9,10].
Figure 2. T cell effector functions of T8-28 cells and susceptibility to killing by allogeneic T cells. (A) T8-28 cells (left) or Con A blasts
(right) were used as effector cells in re-directed lysis assays against A20J cells in the presence or absence of the indicated antibodies. Means 6 SD of
three to six independent experiments are shown. (B) Freshly thawed T8-28 cells were cultured either alone or in the presence of 10
26 M of the
indicated cytokines. Means 6 SD of two to five experiments are shown. (C) Cell recovery after culture of T8-28 cells in the presence of 10
26 M rhIL-2
and paramagnetic beads coated with anti-CD3 and/or anti-CD28 mAbs as indicated. P-values in (B) and (C) are the results of two-way ANOVA testing
against the cells without the specified treatment (‘ø’). (D) Percentage of viable cells as determined by FSC/SSC characteristics among un-stimulated
and PMA/ionomycin re-stimulated T8-28 cells. The figures indicate the number of cells within the life gate. The data are representative for more than
three experiments with comparable results. (E) T8-28 cells are susceptible to killing by allogeneic CD8
+ T cells. CD8
+ cell-depleted allogeneic lymph
node cells (triangles) and lymph node cells cultured without allogeneic APCs (circles) were used as controls. Means of duplicates are shown. The
experiment was repeated with similar result.
doi:10.1371/journal.pone.0028546.g002
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of course, also be an option for the T8-28 lymphoma as, indeed,
for human PTCL [11]. Most likely, a key component of any graft
versus tumor effect in vivo is the recognition and killing of
malignant cells by allo-reactive cytotoxic T cells [12]. As shown in
Figure 2E, T8-28 cells were susceptible to killing by allogeneic
CD8
+ T cells in vitro suggesting that a graft versus tumor effect may
also be elicited upon allogeneic bone marrow transplantation in
vivo.
Taken together, the T8-28 cells constitute a transplantable
PTCL line with, at least, partially defective effector functions but
maintained susceptibility to killing by allogeneic T cells in vitro.
This suggests that this newly established model could provide a
basis for the development of novel immunotherapeutic approaches
for PTCL in humans.
Materials and Methods
Ethics Statement
All experiments were performed according to the German
regulations for animal experimentation and approved by the
Regierung von Unterfranken as the responsible authority (Permit
Number 55.2–2531.01-82/08 and -28/10).
Mice
BALB/c.OlaHsd and C57BL/6.OlaHsd mice were obtained
from Harlan-Winkelmann and were used for experiments between
six and twelve weeks of age. BALB/c mice were irradiated at the
age of nine to ten weeks.
Adoptive transfers of T8-28 cells in vivo
1610
7,5 610
6 or 3610
3 freshly thawed T8-28 cells were
adoptively transplanted intravenously into either un-manipulated
or irradiated syngeneic BALB/c.OlaHsd mice as described [13].
After adoptive transfer of T8-28 cells mice were monitored for
clinical signs of terminal lymphoma such as severe hunching, poor
grooming, lack of spontaneous activity, severe respiratory distress
and/or splenomegaly and animals with terminal disease were
killed for humane reasons.
Fluorescence-activated cell sorting
The following monoclonal antibodies were used (all Becton
Dickinson or Biolegend unless stated otherwise): anti-CD3-FITC
(fluorescein isothiocyanate), anti-CD4 Alexa FluorH 647, anti-
CD8a PE-Cy5 (phycoerythrin-Cy5), anti-CD8b PE, anti-CD25
FITC, anti-T cell receptor (TCR)b PE, anti-TCR Vb 2, 3, 4,
5.1&5.2, 6, 7, 8.1&8.2, 8.3, 9, 10b, 11, 12, 13, 14 and 17a FITC
(BD staining panel), anti-Ki-67 PE, anti-Granzyme B PE
(eBioscience) and unconjugated anti-CD28 (clone E18) [14,15].
Gamouse Ig PE (Dianova) was used to detect bound anti-CD28
mAb.
Stainings, including intracellular stainings, were performed with
up to 2610
5 T8-28 as described [13].
Cytospins
Freshly thawed T8-28 cells and purified (99%) lymph node T
cells from a C57BL/6 mouse, obtained by negative magnetic
selection of cells expressing CD11b, CD11c, CD19, B220, CD49b,
CD105, MHC-class II and Ter-119 according to the manufac-
turer’s instructions (Miltenyi), were spun onto slides and stained
using the Diff-QuikH staining kit (Medion Diagnostics).
Analysis of the T cell receptor b chain by polymerase
chain reaction DNA sequencing
RNA of T8-58 cells was extracted by guanidinium thiocyanate-
phenol-chloroform extraction (TriZol) and transcribed into cDNA
using first strand synthesis kit (Fermentas). PCR of cDNA
was performed using Vb2-leader (59-GTGGCAGTTTTGCA
TTCTGTGCCT-39) and Cbeta specific (59-ACAGTCTGC-
TCGGCCCCAGG-39) primers and Phusion polymerase (Finn-
zymes). The PCR product was separated by agarose gel electropho-
resis. The most prominent band of about 800 bp was extracted and
sequenced on an ABIMed 3100 machine. The sequence was
analyzed by IMGT/V-QUEST programme version: 3.2.20 [16].
In vitro cultures
All in vitro cultures were carried out using RPMI 1640 medium
(PAA) supplemented with 10% heat-inactivated fetal calf serum,
1 mM sodium pyruvate, non-essential amino acids, 100 U/ml
penicillin and 100 mg/ml streptomycin, 30 mM mercaptoethanol
and 2 mM L-glutamine (all Gibco). All cells were incubated at
37uC in the presence of 5% CO2.
Cytotoxic activity of T8-28 cells. To assess the cytotoxic
potential of T8-28 cells, a fixed number of CFSE-labeled (carboxy-
fluorescein succinimidyl ester diacetate; 5 mM; invitrogen) A20J
cells were co-incubated with freshly thawed T8-28 cells in a 96
well V bottom plate at different effector to target cell ratios for four
hours. To trigger re-directed lysis either anti-CD3 mAb 145-2C11
(Biolegend) or anti-b T cell receptor mAb H57-H7 (BD) were
added at a final concentration of 10 mg/ml. To assess the
susceptibility of A20J cells towards apoptotic stimuli, they were
incubated with the anti-CD95 mAb Jo2 (BD) at a final
concentration of 0.1 mg/ml. As a positive control for T cell-
mediated cytolysis we used ‘Con A blasts’, i.e. lymph node cells
(1610
6/ml) of a BALB/c.OlaHsd mouse which we had pre-
activated with Concanavalin A (Con A; 5 mg/ml; Sigma) for three
days in vitro. After the killing period, viability of the A20J target
cells was determined by first counter-staining the cells with
prodidium iodide and AnnexinV APC (BD) followed by
fluorescence-activated cell sorting analysis.
Susceptibility of T8-28 cells to killing by allogeneic T
cells. To generate H-2
d-specific cytotoxic T cells, pooled spleen
and lymph node cells (1610
6/ml) of C57BL/6 mice (H-2
b) were
cultured in the presence of irradiated BALB/c splenocytes
(7.5610
5/ml, H-2
d) and 10
-7 M recombinant human interleukin
2 (ProleukinH, Novartis) for six days. In parallel cultures C57BL/6
spleen/lymph node cells depleted of CD8
+ cells by negative
magnetic separation were used. To deplete CD8
+ cells (99%), the
spleen/lymph node cell suspension was first stained with an anti-
CD8a FITC mAb (BD) followed by anti-FITC beads (Miltenyi)
and passage over an LD column according to the manufacturer’s
instructions (Miltenyi). In further parallel cultures, 2610
6 C57BL/
6 total spleen/lymph node cells were cultured in the presence of
recombinant human interleukin 2 only, i.e. without BALB/c
splenocytes. After the pre-incubation period the effector cells were
washed and co-incubated with a fixed number of 1610
4 CFSE-
labeled T8-28 in a 96 well V bottom plate for four hours. Viability
of the T8-28 target cells was, again, determined by first counter-
staining the cells with propidium iodide and AnnexinV APC (BD)
followed by fluorescence-activated cell sorting analysis.
Short term cultures. For short-term activation, freshly
thawed T8-28 cells (1610
6/ml) were re-stimulated in the
presence of phorbol myristate acetate (PMA)/ionomycin (5/
500 ng/ml, Sigma) for four h before fluorescence-activated cell
sorting analysis.
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impact of recombinant human IL-2 (ProleukinH, Novartis),
recombinant mouse interleukin 7 (R&D) and recombinant
mouse interleukin 15 (Biolegend) on the growth and survival of
T8-28 cells in vitro,1 610
6 T8-28 cells/ml (48 well plate, Greiner)
were cultured in the presence of 10
26 M of exogenously added
cytokine. After re-suspension, 200 ml were removed from each well
on days one, two and five after initiation of the cultures.
The impact of CD3 and/or CD28 stimulation on T8-28 cell
proliferation and survival were studied by incubating freshly
thawed T8-28 cells (1610
6/ml) with 2.5610
6 DynabeadsH Pan
Mouse IgG (Dynal) coated with either 10 mg/ml anti-CD3 mAb
145-2C11 (Biolegend), 10 mg/ml anti-CD28 mAb E18 [14,15],
10 mg/ml mIgG1 mAb PPV-06 (Exbio) or 1 mg/ml anti-CD3 plus
0.5 mg/ml anti-CD28 mAb in the presence of 10
26 M recombi-
nant human interleukin 2. In parallel cultures, only recombinant
human interleukin 2 was added.
To determine absolute numbers of viable T8-28 cells at each
time point, either 2610
5 of the freshly thawed T8-28 cells or all
cells contained in 200 ml of suspension of the cultured cells (initially
also 2610
5 cells) were stained with propidium iodide and
AnnexinV APC before 1610
4 unlabeled CaliBRITE
TM beads
(BD) were added. After fluorescence-activated cell sorting analysis
the absolute number of viable cells was determined as follows:
(1610
4/number of beads recorded) x number of AnnexinV
-
propidium iodide
- T8-28 cells recorded.
Statistics
Summary graphs were generated using Excel
 12.3.0 (Micro-
soft) and p-values are the results of two-way ANOVA testing
(GraphPad Prism 4.0c
). P,0.05 was considered statistically
significant.
Supporting Information
Table S1 In addition to the data shown in Figure 1B, D and E,
further fluorescence-activated cell sorting analyses of T8-28 cells
rendered the results summarized in this table.
(PDF)
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